Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Ensysce Biosciences (ENSC) EBITDA (2020 - 2025)

Historic EBITDA for Ensysce Biosciences (ENSC) over the last 6 years, with Q3 2025 value amounting to -$3.7 million.

  • Ensysce Biosciences' EBITDA fell 68024.32% to -$3.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$11.0 million, marking a year-over-year decrease of 7490.88%. This contributed to the annual value of -$6.7 million for FY2024, which is 3720.83% up from last year.
  • As of Q3 2025, Ensysce Biosciences' EBITDA stood at -$3.7 million, which was down 68024.32% from -$1.8 million recorded in Q2 2025.
  • Over the past 5 years, Ensysce Biosciences' EBITDA peaked at $644746.0 during Q3 2024, and registered a low of -$16.9 million during Q3 2021.
  • For the 5-year period, Ensysce Biosciences' EBITDA averaged around -$3.6 million, with its median value being -$2.6 million (2023).
  • Its EBITDA has fluctuated over the past 5 years, first crashed by 407190.7% in 2021, then surged by 12381.5% in 2024.
  • Quarter analysis of 5 years shows Ensysce Biosciences' EBITDA stood at -$2.0 million in 2021, then crashed by 209.0% to -$6.2 million in 2022, then surged by 49.11% to -$3.2 million in 2023, then decreased by 13.33% to -$3.6 million in 2024, then decreased by 4.6% to -$3.7 million in 2025.
  • Its EBITDA stands at -$3.7 million for Q3 2025, versus -$1.8 million for Q2 2025 and -$2.0 million for Q1 2025.